GTx Inc. had a poster honored as one of the best posters at the 28th Annual European Association of Urology Congress held in Milan Italy March 15 2013.
The poster presentation which had the very long title of “GTx-758 an ERa Agonist Reduces Serum Free Testosterone Lower than can be Achieved by Leuprolide with a Significantly Lower Rate of Hot Flashes in Men with Advanced Prostate Cancer” says it all.
The actual presentation was held on Saturday March 16 2013 in Milan Italy and was a part of the session on New Therapies in Castration Resistant Prostate Cancer. The data that was presented represents findings from a completed Phase II clinical trial of men with advanced prostate cancer. It examined the ability of GTx-758 (Capesaris®) to further reduce the levels of unbound or “free” testosterone in a man’s blood. This finding could potentially limit the cancer’s advancement of becoming castration resistant.
Even with maximal suppression of free testosterone GTx-758 may also by replacing estrogen provide the prospect for an improved quality of life with a better side effect profile than what is more typically experienced by men with advanced prostate cancer treated withthe commonly utilized forms of androgen deprivation therapy (ADT).
Currently, GTx is enrolling an additional Phase II clinical study (G200712) to evaluate the safety and effectiveness of lower doses of GTx-758 to treat men with metastatic castration resistant prostate cancer. The company expects to receive topline data from this study later this year.
This will be a study, as well as the eventual phase 3 trial, for us to continue to watch.
Joel T Nowak, M.A., M.S.W.